# GC Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gc-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.gc-tx.com/
- Total disclosed funding: $65M
- Latest round: Series A (Sep 19, 2024)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded in 2019 by Alex Ng (CSO), Cory Smith, George Church, and Parastoo Khoshakhlagh (CEO), GC Therapeutics Inc. operates as a biotechnology research company focusing on synthetic biology and cell therapy. In September 2024, GC Therapeutics, Inc. raised USD 65 million in Series A funding led by Cormorant Asset Management, with participation from Mubadala Capital, Andreessen Horowitz, Medical Excellence Capital, Cercano Management, and Pear VC.

The firm develops advanced cell therapies using its TFome™ platform, which utilizes induced pluripotent stem cells (iPSCs) to produce therapeutic cells. The technology helps simplify the complexities of cell therapy, allowing for the rapid development and scaling of treatments—potentially achieving improvements in speed, potency, and cost-effectiveness compared to traditional methods. GCTx is targeting therapeutic applications in gastrointestinal, neurological, and immunological diseases.

The company intends to use the September 2024 funding to enhance its TFome platform and accelerate cell therapy development.

## Funding rounds

- Series A, Sep 19, 2024, $65M — Andreessen Horowitz, Cormorant Asset Management, Pear VC, Mubadala Capital, Cercano Management, Medical Excellence Capital

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A
- Cercano Management (https://capitalatlas.ai/funds/cercano-management) — Series A
- Medical Excellence Capital (https://capitalatlas.ai/funds/medical-excellence-capital) — Series A